- ORCID iD
-
0000-0001-9158-0116
Show
Sort by
-
- Journal Article
- A1
- open access
Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis
-
- Journal Article
- A1
- open access
Rapid and continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP
-
Dupilumab reduces asthma disease burden and recurrent SCS use in patients with CRSwNP and coexisting asthma
-
Evaluating treatment responses of dupilumab versus omalizumab in type 2 patients : the EVEREST trial
-
Symptom free days in patients with severe chronic rhinosinusitis with nasal polyps treated with dupilumab
-
- Journal Article
- A1
- open access
Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP
-
- Journal Article
- A1
- open access
AROMA : real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
-
Chronic rhinosinusitis : natural history, impact on health-related quality of life, and patient perspectives
(2022) -
- Journal Article
- A1
- open access
Dupilumab demonstrates rapid onset of response across three type 2 inflammatory diseases
-
Dupilumab achieves durable reduction in severity of symptoms rated most important by patients with chronic rhinosinusitis with nasal polyps
(2022) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 149(2). p.AB142-AB142